Company intelligence / Profile preview

Shenzhen New Industries Material of Ophthalmology

Shenzhen, Guangdong, Chinabloomberg.com ↗

Ownership: Private
Employees: ~1000
Development stage: Commercial

Overview

Snibe has developed and commercialized automated chemiluminescence immunoassay analyzers and a broad menu of in vitro diagnostic reagents. Their MAGLUMI series systems are widely used in clinical laboratories worldwide, with regulatory clearances including FDA approval for some products. The company continues to innovate in high-throughput and integrated diagnostic solutions. No direct clinical trial results as they do not develop therapeutics.

Therapeutic areas: Other
Modalities: DeviceDiagnostic reagent (In vitro diagnostic reagents)
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

diquafosol sodium

Commercial

Indications: Dry eye syndrome

Beyond the preview

Go deeper on Shenzhen New Industries Material of Ophthalmology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenzhen New Industries Material of Ophthalmology.

Explore the full profile